Compare Natera Inc. Common Stock (NTRA) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs J M Smucker Co — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while J M Smucker Co trades at $122 (market cap $13.02B). The key difference: Natera Inc. Common Stock is far larger — about 4.4× J M Smucker Co's market cap, and J M Smucker Co pays a 3.68% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and J M Smucker Co for 74 Days on average.
| NTRA | SJM | |
|---|---|---|
Market Cap | $57.03B | $13.02B |
Volume | 1,131,157 | 1,012,147 |
Sector | Health | Consumer Staples |
52-Week High | $425.64 | $132.34 |
52-Week Low | $179.42 | $89.53 |
Typical Hold Time | 0 Days | 74 Days |
Enterprise Value | $56.18B | $19.87B |
Dividend Yield | — | 3.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
SJM trades at $121.33, up 1.09% today, with a bullish technical signal and strong support at $120. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026, alongside a 51.61% analyst buy rating, highlight positive momentum. However, the P/E ratio of 56.7 is elevated, and 2025 net income was -$1.23B, reflecting profitability challenges despite revenue growth to $8.73B.
The outlook is mixed: analyst consensus targets $138.23, suggesting 14% upside, and robust cash flow supports dividends. Risks include high debt-to-asset ratio (43.71% in 2025) and volatile earnings. Investors should weigh growth in brands like Uncrustables against margin pressures and competitive threats in the consumer staples sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
